Catalyst Brief

← Calendar

Readoutin 14d

Sichuan Baili Pharmaceutical Co., Ltd. — BL-B01D1

Phase 3 primary completion: A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02).

Date
Dec 2026
Type
Readout
Indication
Non-small Cell Lung Cancer

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Sichuan Baili Pharmaceutical Co., Ltd.

  1. Dec2026